1,000 ovarian cancer patients to be tracked for Gene-Treatment links
NCT ID NCT05574673
First seen Mar 10, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This study follows 1,000 women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Participants receive usual care, and researchers collect data on surgery, chemotherapy outcomes, and survival. The goal is to better understand which treatments work best for different genetic profiles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rigshospitalet
RECRUITINGKøbenhavn Ø, Region Sjælland, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.